1. Anabalón L, Araya J, Bravo M, Guzmán P, Roa J, Roa I, et al. Relación de la genotipificación de Helicobacter pylori con la forma e intensidad de la gastritis en población adulta portadora de patología gástrica benigna. Rev Med Chile 2004;132:1345-54. Disponible en URL: http://www.scielo.cl/pdf/rmc/v132n11/art02.pdf

2. Borda F, Echarri A. Infection by Helicobacter pylori and gastric cancer. ANALES Sis San Navarra 1998;21(2):45-53. Disponible en URL: http://www.cfnavarra.es/salud/anales/textos/vol21/suple2/pdf/05infe.pdf

3. Konturek PC, Konturek SJ, Pierzchalski P, Bielański W, Duda A, Marlicz K, et al. Cancerogenesis in Helicobacter pylori infected stomach ? role of growth factors, apoptosis and cyclooxygenases. Med Sci Monit 2001;7(5):1092-1107

4. Blaser M. Origen bacteriano de la úlcera de estómago. Rev. Investigación y Ciencia. Abril 2005; 235. Disponible en URL: http://coli.usal.es/web/articulos/art14/art14.htm

5. Jawetz, Melnick, Adelberg. Microbiología Médica. 18 ed. México. Manual Moderno; 2004

6. Naumann M, Crabtree J. Helicobacter pylori ? induced epithelial cell signalling in gastric carcinogenesis. Trends Microbiol Jan 2004;12(1):29-36

7. Xiang Z, Censini S, Bayeli P, Telford J, Figura N, Rappuoli R et al. Analysis of Expression of CagA and VacA virulence Factors in 43 Strains of H. pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Inmun Jan 1995;63(1):94-8

8. Ocadiz R, Sobrino S, García L, Marroquín A, Hernández R, Gariglio P. Relación entre la infección por H. pylori y el desarrollo de metaplasia en pacientes con gastritis crónica. Rev Bioquimia [online] Enero-Marzo 2005;30(1):13-22. Disponible en: <http://www.medigraphic.com/pdfs/bioquimia/bq-2005/bq051c.pdf

9. García F. Vacunas contra H. pylori: ¿una alternativa con impacto global contra el cáncer gástrico? Rev Costarric Salud pública [online] dic2002;[citado 08 Abril 2007] 11(21):32-6. Disponible en URL: <http://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S140914292002000200007&Ing=pt&nrm=iso>.ISSN1409-1429

10. Hernández F, Freer E. H. pylori, cáncer gástrico y dispepsias no ulcerosas: los nuevos motivos de discusión. Rev Costarric Cienc-med. [online]. Sept 1997 [Citado 15 abril 2007]; 18(3):55-9, Disponible en URL:http://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S025329481997000300007&Ing=pt&nrm=iso>.ISSN0253-2948

11. Seoane A, Bessa X, Alameda F, Munné A, Gallen M, Navarro S et al Papel del H. pylori en el cáncer gástrico tras gastrectomía parcial por úlcera benigna. Rev Esp Enferm Dic 2005 [citado 2007-04-08];97(11):778-85. Disponible en URL: http://wwwscielo.isciii.es/scielo.php?script=sci_arttexr&pid=S113001082005001100002&Ingnrm=iso.ISSN1130-0108

12. Pinol F, Salvador J, Paniagua M, Borbolla E. Características de la infección por H. pylori en pacientes con adenocarcinoma gástrico. Rev Cubana med [online]. sept?dic2005 [citado 08 Abril 2007];44(5-6): p. 0-0. Disponible en URL: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S00347523200500002&Ing=es&nrm=iso%3E.ISSN0034-7523

13. Infante F, Rangel C, Rojas M, Vivas O, Marcano M. Modelo teórico de respuesta inmunológica en la mucosa gástrica en la infección por Helicobacter pylori. VITAE 2006;26

14. Champoux J, Drew W, Neidhardt F, Plorde J. Medical Microbiology: An introduction to infectious diseases. In: Ryan K, Ray C, editors. Vibrio, Campylobacter y Helicobacter. 4^th ed. NewYork: Mc Graw Hill; 2004. p. 413-7.

15. Graham D, Sepulveda A. Role of Helicobacter pylori in gastric carcinogenesis. Gastroenterol Clin N Am, 2002; 31(517?35)

16. Cover T, Israel D, Krishna U, Peek R. Induction of Gastric Epithelial Cell Apoptosis by Helicobacter pylori Vacuolating Cytotoxin. Cancer Research. March 2001 (63) 951-7. Disponible en URL: http://cancerres.aacrjournals.org/cgi/reprint/63/5/951

17. Boquet P, Ricci V, Galmiche A, Gauthier N. Gastric cell apoptosis and H. pylori: has the main function of VacA finally been identified?. TRENDS in Microbiology. Sept 2003;11(9):1-4

18. Paniagua M, Pinol F. Mediadores bacterianos de la inflamación en la gastritis crónica por Helicobacter pylori. Rev cubana med. [online]. oct.-dic. 1999;38(4) [citado 17 Mayo 2007], p.276-83. Disponible en: <http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75231999000400007&lng=es&nrm=iso>. ISSN 0034-7523

19. Crabtree J. Role of cytokines in pathogenesis of Helicobacter pylori-induced mucosal damage. Dig Dis Sci 1998;43:46-55

20. Gerhard M, Lehn N, Neumayer N, Rad R, Schepp W, Miehlke S, Classen M, et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci U S A 1999;96:12778?83

21. Yu J, Leung W, Go M, Chan M, To F, Ng E, et al. Relationship between Helicobacter pylori babA2 status with gastric epithelial cell turnover and premalignant gastric lesions. Gut 2002;51:480-4

22. Dorrel N, Farthing M, Martino C, Stabler R, Wren B, Zhang Z. Helicobacter pylori pore-forming Citolysin Orthologue Tlya Possesses In Vitro Hemolytic Activity and Has a Role in Colonization of the Gastric Mucosa. Infect Immun 2001;69(3):1697-1703

23. Ansorg R, Rein A, Von Reckling G. Cell-associated hemolytic activity of Helicobacter pylori. Clin Microbiol Infect Dis 1993;12:98?104

24. Rowe G, Welch R. Assays of hemolytic toxins. Methods Enzymol 1994;235:657?67

25. Drazek S, Dubois A, Holmes R, Kersulyte D, Akopyants N, Berg D, et al. Cloning and Characterization of Hemolytic Genes from Helicobacter pylori. Infect Immun 1995;63(11):4345?9

26. Tolwinski N, Wieschaus E. Rethinking Wnt signaling. Trends genet 2004;20:177-81).

27. Tsukashita S, Kushima R, Bamba M, Nakamura E, Mukaisho K, Sugihara H. Beta-catenin expression in intramucosal neoplastic lesions of the stomach. Comparative analysis of adenoma/dysplasia, adenocarcinoma and signet-ring cell carcinoma. Oncology 2003; 64:251-58

28. Franco A, Israel D, Washington M, Krishna U, Fox J, Rogers A, et al. Activation of β-catenin by carcinogenic Helicobacter pylori. Oncology 2003;64:251-8

29. Houghton J, Wang T. Tumors of Stomach In: Feldman M, Friedman L, Brandt L, editores. Sleisenger and Fordtran´s Gastroitestinal and Liver Disease. 8 ed. Philadelphia: rav en press; 2006. p. 1139-6

30. Bauerfeind P, Garner R, Mobley H. Allelic Exchange Mutagenesis of nixA in Helicobacter pylori results in Reduced Níkel Transport and Ureasa Activity. Infect Immu 1996;64:2877-80

31. McGee D, May C, Garner R, Himpsl J, Mobley H. Isolation of Helicobacter pylori Genes that Modulate Ureasa Activity. J Bacteriol 1999;181:2477-84

32. McGee D, Coker C, Testerman T, Harro J, Gibson S, Mobley H. The Helicobacter pylori flbA flagellar biosynthesis and regulatory gene is required for motility and virulence and modulates urease of H. pylory and Proteus mirabilis. J Med Microbiol 2002;51:958-70

33. Olivares J, Gisbert J, Pajares J. Infeccion por Helicobacter pylori y Apoptosis de las Células Epiteliales de la Mucosa Gástrica. Rev Esp Enferm Dig 2005;97:505-20)

34. Konturek P, Hartwich A, Zuchowicz M, Labza H, Pierzchalski P, Karczewska E, et al. Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer. J Physiol Pharmacol 2000;51:737-49

35. Sum il M, Sum il K, Tari A, Kawaguch H, Yamamoto G, Takehara Y, et al. Expression of antral gastrin and somatostatin in Helicobacter pylori infected subjects. Am J Gastroenterol. 1994;89:1515-9

36. Kouturek J. Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori. J Physiol Pharmacol. 1994;45:3-66

37. Graham DV, Opekun A, Lew GM, Klein P, Walsh JH. Helicobacter pylori associated exaggerated gastrin release in duodenal ulcer patients. The effect of bombesin in fusion and urea ingestion. Gastroenterology. 1991;100:1571-5

38. Van Der Wouden E, Thijs J, Van Zwet A, Kleibeuker J. Review Article: Nitroimidazole Resistance in Helicobacter pylori. Aliment Pharmacol Ther 2000;14:7-14

39. Xia H, Keane C, Beattie S, O`Morain C. Standardization of Disk Diffusion test and its Clinical Significance for Susceptibility Testing of Metronidazole against Helicobacter pylori. Antimicrob Agents Chemother 1994;38:2357-61

40. Gerrits M, Van Vliet A, Kuipers E, Kusters J. Helicobacter pylori and Antimicrobial Resistance: Molecular Mechanisms and Clinical Implications. Lancet Infect Dis 2006;6: 699-709

41. Frenck R, Clemens J. Helicobacter in the Developing World. Microbes Infect 2003;5:705-13

42. Megraud F. Resistance of Helicobacter pylori to Antibiotics. Aliment Pharmacol Ther 1997;11:43-53

43. Mendonca S, Ecclissato C, Sartori M, Godoy A, Guerzoni R, Degger M, et al. Prevalence of Helicobacter pylori Resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and furazolidone in Brazil. Helicobacter 2000;5:79-83

44. Marshall BJ, Armstrong J, McGechie D, Glancy R. Attempt to Fulfil Koch´s Postulates for Pyloric Campylobacter. Med J Aust. 1985;142:436-39

45. Gisbert J, Pajares J. Treatment of Helicobacter pylori Eradication Failures. Curr Treta Options Gastroenterol 2003;6:147-56

46. Ellis R. The molecular chaperone concept. Semin Cell Biol 1990; 1:1-9

47. Sharma S, Millar G, Peek R, Perez G, Blaser MJ. T-cell, antibody, and cytokine responses to homologs of the 60-kilodalton heat shock protein in Helicobacter pylori infection. Clin Diagn Lab Immunol 1997;4:440-46

48. Yamaguchi H, Osaki T, Kurihara N, Kitajima M, Kai M, Takahashi M, et al. Induction of secretion of interleukin-8 from human gastric epithelial cells by heat shock protein 60 homologue of Helicobacter pylori. J Med Microbiol 1999; 48:927-33

49. RyutaT, Kenji Y, Kiyoshi A, Motowo M,Ying Z, Yoshihito F, et al. Helicobacter pylori heat-shock protein 60 induces inflammatory responses through the Toll-like receptor triggered pathway in cultured human gastric epithelial cells. Microbiol 2004 Dec;150:3913-22

50. Hayashi S, Sugiyama T, Yokota K, Isogai H, Isogai E, Oguma K, et al. Analysis of immunoglobulin A antibodies to Helicobacter pylori in serum and gastric juice in relation to mucosal inflammation. Clin Diagn Lab Immunol 1998;5:617?21

51. Smith M, Mitchell A, Li G, Ding S, Fitzmaurice A, Ryan K, et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells. J Biol Chem 2003;278:32552?60

52. Gobert A, Bambou J, Werts C, Balloy V, Chignard M, Moran A, Ferrero R. Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a toll-like receptor (TLR) 2-, TLR-4-, and myeloid differentiation factor 88-independent mechanism. J Biol Chem 2004; 279:245?50

53. Martínez J. Caracterización molecular de cepas de Helicobacter pylori. Reproducción del modelo animal en ratones y estudio de los mecanismos de la inflamación.Universidad de Barcelona. May 2001(pp. 8-10). Disponible en URL: http://www.tdx.cesca.es/TESIS_UB/AVAILABLE/TDX-0124102-151944//TESIS.pdf

54. Aspholm-Hurtig M, Ilver D, Unemo M. The Sialic acid binding SabA adhesin of Helicobacter pylori is essential for nonopsonic activation of human neutrophils. J Biol Chem 2005;208:15390-97

55. Dawn I, Peek R. The Role of Persistence in Helicobacter pylori Pathogenesis. Curr Opin Gastroenterol 2006;22(1):3-7

56. Gubert A, Katar M, McGee D. Helicobacter pylori Arginase Inhibits Nitric Oxide Production by Eukaryotic Cells: a Strategy for Bacterial Sourvival. Proc Natl Acad Sci USA 2001;98:13844-9

57. Akhiani A, Franzen L, Schon K. Helicobacter pylori ? Specific Antibodies Impair the Development of Gastritis, Facilitate Bacterial Colonization, and Counteract Resistence Against Infection. J Immunol 2004;172:5024-33

58. Brandt S, Hartig R, Kwok T. NF-kB Activation and Potentiation of Proinflammatory Responses by the Helicobacter pylori CagA protein. Proc Natl Acad Sci USA 2005;102:9300-5

59. Higashi H, Ishikawa S, Yokoyama K. Funcional Antagonism between Helicobacter pylori CagA and Vacuolating Toxin VacA in Control of the NFAT Signaling Pathway in Gastric Epithelial cells. Proc Natl Acad Sci USA 2005;102:9661-6

60. Gubert B, Fisher W, Weiss E. Helicobacter pylori Vacuolating Cytotoxin Inhibits T Lymphocyte Activation. Science 2003;301:1099-1102

61. El Omar EM. The importance of interleukin-1beta in Helicobacter pylori associated disease. Gut 2001;48:743-7 Disponible en: URL: http://gut.bmj.com/cgi/content/full/48/6/743?ijkey=8291f08746d492080d53028db8b357796ebba48d&keytype2=tf_ipsecsha

62. Figueiredo C, Machado J, Pharoah P, Seruca R, Sousa S, Carvalho R, et al. Helicobacter pylori and Interleukin 1 Genotyping: An Opportunity to Identify High-Risk Individuals for Gastric Carcinoma. JNCI, 2002 94(22):1680-7. Disponible en: URL: http://jnci.oxfordjournals.org/cgi/content/full/94/22/1680#BIBL

63. Espinoza M. Factores de riesgo y tipos de cáncer gástrico, en pacientes con biopsias estudiadas en el Departamento de Patología del HEODRA en el período de Enero 2005- Noviembre 2006. UNAN-LEON Febrero 2007; 8-16. Disponible en: URL: http://www.minsa.gob.ni/bns/monografias/2007/patologia/C%E1ncer_G%E1strico.pdf

64. Alameda F, Bessa X, Gallen M, Seoane A, Munné A, Navarro S, et al. Papel de H. pylori en el cáncer gástrico tras gastrectomía parcial por úlcera benigna. Rev Esp Enferm Dig [online].2005 [citado 2007-04-08], 97 (11), pp.778-785. Disponible en: http://wwwscielo.isciii.es/scielo.php?script=sci_arttexr&pid=S113001082005001100002&Ingnrm=iso.ISSN1130-0108

65. Leodolter A, Malfertheiner P, Peitz U. Cure of Helicobacter pylori-associated ulcer disease through eradication. Baillieres Best Pract Res Clin Gastroenterol 2000;14 (1):119-32

66. Gisbert JP. Recurrencia de la infección por Helicobacter pylori. En: Pajares García JM, Correa P, Pérez Pérez GI, eds. Infección por Helicobacter pylori en lesiones gastroduodenales. La segunda década. Barcelona: Prous Science, 1998. p. 263-78

67. Jeen Y, Kwon S, Lee S, Lee HS, Chun HJ, Song CW, et al. Differentiation between reinfection and recrudescence of Helicobacter pylori strains using PCR-based restriction fragment length polymorphism analysis. Yonsei Med J 2001;42(1):41-5

68. Aydin A, Ersoz G, Ozutemiz O, Tuncyurek M. Low reinfection rate of Helicobacter pylori infection in Turkey. J Clin Gastroenterol 2000;30(3):337

69. Gurbuz AK, Ozel AM, Yazgan Y, Celik M, Yildirim S. Oral colonization of Helicobacter pylori: risk factors and response to eradication therapy. South Med J 2003;96 (3):244-7

70. Barba M, Boixeda D, Cantón R, García A, García-Aranda I, Gisbert J, et al. Role of partner's infection in reinfections after H. pylori eradication. Eur J Gastroenterol Hepatol 2002;14:865-71

71. De Angelis A, Leone N, Pellicano R, Peyre S, Repici A, Rizzi R, et al. The effect of the eradication of Helicobacter pylori infection on hemorrhage because of duodenal ulcer. J Clin Gastroenterol 2001;32(3):222-4

72. Arefin M, Bardhan P, Hildebrand P, Parvin S, Rahman A, Rossi L, et al. Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladesh adults. Gastroenterology 2001;121(4):792-8

73. Chang F, Chen T, Lee S, Tsay S. Recurrence of H. pylori infection and dyspeptic symptoms after successful eradication in patients cured of duodenal ulcer disease. Hepato-Gastroenterology 1999;46(25):252-6

74. Erttmann R, Horstmann M. Relapse of MALT lymphoma associated with Helicobacter pylori after antibiotic treatment. Lancet 1994;343:1098-9

75. Borda F, Domínguez J, Ducons J, Gisbert JP, Gomollon F, Mino G, et al. Validación de la prueba del aliento con 13C-urea para el diagnóstico inicial de la infección por Helicobacter pylori y la confirmación de su erradicación tras el tratamiento. Rev Esp Enferm Dig 2003;95(2):115-20

76. Gómez B, Rojas M, García M, Romero R, Hergueta P, Pellicer F. et al. Incidence and factors influencing on Helicobacter pylori infection recurrence. Rev Esp Enferm Dig [serial on the Internet]. Sep 2004 [citado22 Mayo 2007]; 96(9): 620-627. Disponible en: http://wwwscielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082004000900005&lng=en&nrm=iso

77. Fock K, Khor C, Ng T, Tan A, Teo E, Sim C, et al. Recurrence of Helicobacter pylori infection and duodenal ulcer relapse, following successful eradication in an urban east Asian population. Singapore Med J 2000;41(8):382-6

78. Carta M, Casu M, Dore M, Idda M, Realdi G. Effect of cure rate on reinfection with H. pylori: a three-year, follow-up study. Am J Gastroenterol 2000;95(11):3324-5

79. Mena F. Las bases moleculares del cáncer gástrico (la mejor forma de vencer a un enemigo, es conociendolo). Acta méd costarric [online]. jun. 2002, 44 (2) [citado 21 Mayo 2007]:53-54. Disponible en: <http://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S0001-60022002000200002&lng=es&nrm=iso>. ISSN 0001-6002

80. Dyer A, Elliott P, Hill M, Joossens J, Lesaffre E, Stamler R, et al. Dietary salt, nitrate and stomach cancer mortality in 24 countries. European cancer prevention. Int J Epidemiology 1996;25:495-504. Disponible en URL: http://ije.oxfordjournals.org/cgi/reprint/25/3/494

81. Llorens P, Medina E, Nakamura K, Navarro A, Saénz R, Takeshita. Cáncer Gástrico. Editor Llorens P. Epidemiología del Cáncer gástrico. Chile: Editorial IKU; 2001 p. 13-26. Disponible en URL: http://www.saval.cl/medios/medios/centro/contenidos/pdf/cancerGastrico.pdf

82. Contardo C. Rol del Helicobacter pylori en la patología tumoral gastroduodenal. Revista de Gastroenterología del Perú 1997; 17(1). Disponible en: http://sisbib.unmsm.edu.pe/BvRevistas/gastro/vol_17s1/rol_helicobacter.htm

83. O´Connor F, Buckley M, O´Morain C. H. pylori: the cancer link. JR Soc Med 1996;89:674-8

Brenner H, Luzza F, Imeneo M, Maletta M, Pallone F. Smoking, alcohol and coffe consumption, and H. pylori infection. BMJ March 1998;316:1019. Disponible en URL: http://www.bmj.com/cgi/content/full/316/7136/1019